Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX) announced a conference call scheduled for February 28, 2022, at 4:30 pm ET, to discuss its fourth-quarter and year-end 2021 financial results. The call will also include a corporate update. Ardelyx recently received approval for IBSRELA (tenapanor), with plans for its launch in Q2 2022. The company is advancing tenapanor for managing serum phosphorus in adult CKD patients on dialysis and developing RDX013 for hyperkalemia treatment. Global partnerships have been established for tenapanor's commercialization in Japan, China, and Canada.

Positive

• Approval of IBSRELA (tenapanor) with Q2 2022 launch planned.
• Successful completion of three Phase 3 trials for tenapanor.
• Partnerships established for tenapanor development in Japan, China, and Canada.

Negative

• None.

WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Monday February 28, at 4:30 pm Eastern Time to discuss fourth quarter and year-end 2021 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 2790368. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx, Inc.

Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to meet significant unmet medical needs. Ardelyx received approval for IBSRELA (tenapanor) with plans to launch in the second quarter of 2022. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.  Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-report-fourth-quarter-and-year-end-2021-financial-results-and-provide-corporate-update-on-february-28-2022-301487152.html

SOURCE Ardelyx

FAQ

When will Ardelyx report its fourth-quarter and year-end 2021 financial results?

Ardelyx will report its financial results on February 28, 2022.

What is the significance of IBSRELA for Ardelyx?

IBSRELA (tenapanor) is significant as it received approval and is set to launch in Q2 2022, addressing unmet medical needs.

What are Ardelyx's plans for tenapanor?

Ardelyx plans to use tenapanor to control serum phosphorus in adult CKD patients on dialysis and has completed three successful Phase 3 trials.

What developments are underway for RDX013?

RDX013 is being developed as a treatment for elevated serum potassium, a condition affecting certain kidney and heart disease patients.